Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Sexual-Health

Gonadorelin

GnRH; LHRH; Factrel

GnRH decapeptide (FDA-approved)

This Gonadorelin entry draws on 9 cited sources published 2015 to 2026. The evidence available is graded FDA-Approved on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
GnRH decapeptide (FDA-approved)
Drug class
Sexual-Health
Structure
Decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
Route
SC / IV
Half-life
~10-40 min
Evidence tier
FDA-Approved
Availability
Prescription
Research depth
171 indexed citations (PubMed 117 · CT 11 · EPMC 43) →

Mechanism of action

GnRH receptor agonist on pituitary; pulsatile stimulation of LH/FSH

Reported areas of research

LH/FSH stimulation; testosterone support; supports testicular function during exogenous testosterone use

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

100 mcg SC 2x weekly (TRT adjunct starting dose, may go up to 300 mcg per dose 3x weekly per community protocols); 5 mcg IV pulses every 90 minutes (Lutrepulse pump for infertility)

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Pituitary desensitization with continuous infusion

Compared with

Gonadorelin has published head-to-head comparisons with 1 compound that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for Gonadorelin in research literature?

Published peptide research reports the following dosing approach for Gonadorelin: 100 mcg SC 2x weekly (TRT adjunct starting dose, may go up to 300 mcg per dose 3x weekly per community protocols); 5 mcg IV pulses every 90 minutes (Lutrepulse pump for infertility). This is a research reference, not a clinical recommendation.

How is Gonadorelin administered in research?

Gonadorelin is administered via the following routes in published studies: SC / IV.

What is the reported half-life of Gonadorelin?

The reported half-life of Gonadorelin is ~10-40 min.

Is Gonadorelin FDA-approved?

Yes. Gonadorelin is an FDA-approved drug. PeptideHelper.org catalog status: Prescription.

What level of evidence supports Gonadorelin?

The current evidence base for Gonadorelin is best characterised as: FDA-Approved. See the methodology page for the full evidence-tier rubric.

What side effects are reported for Gonadorelin?

Known concerns reported in the literature for Gonadorelin include: Pituitary desensitization with continuous infusion. Always consult a qualified clinician before any human use.

Is there anyone who should not use Gonadorelin?

Gonadorelin is FDA-approved, but no contraindications section was retrievable from its current label, so none is reproduced here. Consult the prescribing information and a qualified clinician before any human use.

How does Gonadorelin work?

The mechanism of action reported for Gonadorelin in the literature: GnRH receptor agonist on pituitary; pulsatile stimulation of LH/FSH.

What is Gonadorelin studied for?

Gonadorelin has been studied in the published literature for: LH/FSH stimulation; testosterone support; supports testicular function during exogenous testosterone use. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is Gonadorelin?

Gonadorelin is classified as: GnRH decapeptide (FDA-approved). Also known as: GnRH; LHRH; Factrel.

Research focus area

All peptides studied for Sexual-Health, ranked by evidence tier and regulatory status.

Primary sources

  1. FDA Factrel (gonadorelin hydrochloride) prescribing information
  2. Binder G et al. Inhibin B plus LH vs GnRH agonist test for distinguishing constitutional delay of puberty from isolated hypogonadotropic hypogonadism. Clin Endocrinol (Oxf) 2015. PMID 25207430
  3. Rebeis LM et al. Recombinant bovine somatotropin at synchronization initiation, but not at embryo transfer, enhances fertility in embryo-recipient heifers: Associations with follicular, luteal, and embryonic outcomes. Journal of dairy science 2026. PMID 42336048
  4. da Silveira GM et al. A new cetrorelix-based estrogen-free ovarian synchronization protocol for fixed-time artificial insemination in beef cattle. Theriogenology 2026. PMID 41864162
  5. Lima FS et al. Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows. Journal of dairy science 2026. PMID 41698585
  6. López-Gatius F et al. Effect of post-insemination GnRH analogue administration on pregnancy rates in repeat-breeder cows: comparison of dosage and frequency. The Journal of reproduction and development 2026. PMID 42091524
  7. Cho MH et al. Diagnostic Usefulness of Subcutaneous Triptorelin Stimulation Testing in the Evaluation of Central Precocious Puberty in Girls. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2026. PMID 41956123
  8. Ozturk B et al. Stress-related cortisol and progesterone concentrations influence the success of ovulation induction in estrous cats. Theriogenology 2026. PMID 41579561
  9. eSilva LO et al. Effects of high frequency administration of GnRH or kisspeptin on LH pulse and surge profiles in ovariectomized Bos taurus and Bos indicus heifers†. Biology of reproduction 2026. PMID 42725801

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…